The PennZone

  • Home
  • Non-profit
  • Education
  • Business
  • Construction
  • Entertainment
  • Technology
  • Health
  • Software

ExpressCells Completes Series A2 Financing
The PennZone/10119466

Trending...
  • Virginia Moving Company Nearly Doubles Customer Calls in Two Weeks After Switching to CARL — the Bold New Alternative to WordPress
  • Why Athletic Recovery Begins in the Nervous System
  • A Hidden Magical World Awaits in Ashley Gayheart's Upcoming Young Adult Fantasy, Rosewood Academy: The Awakening
Extension of Series A Supports Operations Expansion and Increased Promotion

PHILADELPHIA - PennZone -- ExpressCells, Inc., a private genetic engineering company that creates knock-in cell lines to support biological research, today announced that it has completed an extension of its Series A financing round. The company raised $590,500 in this Series A2 round from both existing and new investors. This round was oversubscribed by 18%.

New investors in ExpressCells include the MIT Alumni Angels of Northern California, the Orange County Chapter of Tech Coast Angels, and the Berkeley Angel Network. Existing investors who also invested in this round include the Rowan Innovation Venture Fund, the Central Texas Angel Network, Robin Hood Ventures, and Ben Franklin Technology Partners of Southeastern Pennsylvania.

ExpressCells is using the $590,500 raised in this round to expand its operational infrastructure to support the increasing demand for its knock-in cell lines. The company also will increase promotion to the biological research community.

More on The PennZone
  • ICTPBX Released: White-Label, Multi-Tenant Open Source PBX Platform for ITSPs
  • 5,521 College Athletes Launch Own Merch Stores in Just 30 Days on AthleteMerch.com, Reaching 7,975 Live Storefronts Nationwide
  • Altruvest and Financial Executives International Canada Announce Strategic Partnership to Strengthen Nonprofit Boards Across Canada
  • Dr. Dee for the People: A Vision of Hope, Healing, and Transformation for Philadelphia
  • Free Critical Illness Claim Calculator Launches to the Public

"This funding allows ExpressCells to meet the rapidly-growing demand from both industry and academic customers. We are thankful to the new investors who have joined our Series A," said Matt Handel, co-founder and CEO of ExpressCells. "We also appreciate the additional funding from our existing investors."

Interest in this round of financing was driven, in part, by recent news events for ExpressCells. Pepperdine Graziadio Business School named ExpressCells to its 2020 Most Fundable Companies® List and ExpressCells was one of top three startups—and the top life sciences company—in the Pismo Venture's National Venture Plan Competition.

About ExpressCells

ExpressCells uses its proprietary genome editing technology, in combination with CRISPR/Cas9, to create advanced, knock-in cell lines to enhance drug discovery and other types of biological research. The speed of the process allows ExpressCells to insert one to three genes into the same cell line months faster than other technologies. The company currently has 17 customers and expects that number to grow.

ExpressCells sells both custom and catalog cell lines. For more information, visit xpresscells.com (http://www.xpresscells.com/).

Contact
ExpressCells, Inc.
***@xpresscells.com


Source: ExpressCells, Inc.

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • HealthBook+ and Stonebrook Risk Solutions Partner to Bring Predictive Intelligence to Healthcare Risk
  • Umbrella Becomes First FinOps Platform to Support AWS Billing Transfer Onboarding
  • RECYCLEXPERT FZE Strengthens Leadership in Data Destruction UAE and GCC with Certified Secure ITAD Services
  • Plasma-Activated Nitric Oxide Cream Outperforms L-Arginine Skincare - New Research Explains Why
  • Assymetrix Launches the Deepest Independent Prediction Market Data API
  • CCHR: 'Plant-Based' Psychedelics Push Masks Synthetic Drugs and Billion-Dollar Profits
  • BTR: i2 Group Launches i2 Amplify, a Community Platform for Intelligence Professionals Worldwide
  • L.A. Watts Summer Games Announces Free Pelé Tribute Event at Magic Johnson Park
  • SUMOFIBER Fuels Explosive Growth With netElastic vBNG
  • Brian Keenan Joins ALLY Construction Services as Director of Business Development
  • Burkentine Builders Recognizes Local Fire Departments As Part Of Their Live With Purpose Initiative
  • God's Meal Barrel Raises $3,135 During Give Local York
  • NRx Pharmaceuticals (N A S D A Q: NRXP) Accelerates Into National Spotlight as Manufacturing Launch, Federal Policy & AI-Driven Breakthroughs Converge
  • Expanding Into High-Margin Battery Recycling With Black Mass Strategy plus Scaling AI Infrastructure & Global Supply Chain Platform: N A S D A Q: MWYN
  • Long-Distance Couples Spend Nearly $7,000 on Travel Before Moving In Together, New Mayflower Research Finds
  • Pittsburgh Author Embraces Wisdom in The Principal Thing
  • "I'm Sicka Church Too: Give Me Kingdom!" Ignites a Powerful Call for Healing and Truth
  • imggpt Launches AI-Powered GPT Image Generator and Photo Editor for Creative Teams
  • Intuitive Flow Systems Launches Mokēd Meditation Whistle
  • More Life Summit 2026 Announces Gary Brecka & Mr. Olympia Derek Lunsford as First Speakers for Miami Event

Popular on PennZone

  • 300 Episodes. One Mission: Brother Marcus Ignites a Global Movement of Inspiration - 139
  • The Finger Comb, a Dream Inspired 3-in-1 Styling Tool introduced by Andrea L. Randolph - 113
  • From Speech Therapy to 300+ Episodes: Brother Marcus Turns His Voice Into a Movement Launching a 24/7 Inspiration Radio Network on Day 100 of the Year
  • Mensa Brings National Board Game Competition to Northern Virginia April 16-19
  • Porter's Day Care Empowers Philadelphia's Future Through 45+ Years of Excellence
  • Bishop Mary's WWDB 860 AM Show Nears Historic 250-Episode Milestone
  • Dog Grooming Businesses Turn to Performance-Based Platforms to Attract Local Clients
  • Eastern Adjustment Group, LLP Provides Property Loss Advocacy and Claim Support
  • Bold Beauty Project Announces Exhibition at Palazzo Mora Venice, Italy
  • New plusOne Research Finds the Orgasm Gap Is a 30-Point Chasm — and Confirms It Isn't Biology

Similar on PennZone

  • NRx Pharmaceuticals (N A S D A Q: NRXP) Accelerates Into National Spotlight as Manufacturing Launch, Federal Policy & AI-Driven Breakthroughs Converge
  • More Life Summit 2026 Announces Gary Brecka & Mr. Olympia Derek Lunsford as First Speakers for Miami Event
  • Presidential Acceleration of Psychedelic Therapies Enters a Defining Moment as Federal Policy, FDA Alignment & Breakthrough Neurotechnology Converge
  • Dual-Engine Growth Strategy Unleashed Targeting a $9.1B Market and the Exploding AI Biotech Revolution: KALA BIO (N A S D A Q: KALA)
  • AI-Driven Neurotechnology Expansion as FDA Path Clears and New Defense Initiative Emerges for NRx Pharmaceuticals (N A S D A Q: NRXP)
  • Charging Into the $30 Billion Heart Failure Market with Late-Stage Momentum, Breakthrough Data, & Strong Financial Backing: Cardiol Therapeutics $CRDL
  • Instant IP Teams: Bringing Enterprise-Grade Collaboration to IP Protection at the Speed of Thought
  • Boston Industrial Solutions Expands Its Industry-Leading UV Ink Portfolio with the Launch of a Matte Ink - Natron® UVPZ
  • AI-Driven Breakthrough Unleashed: Bionic Intelligence Platform Goes Live to Capture Massive Biotech Opportunity: KALA BIO, Inc. (N A S D A Q: KALA)
  • NRx Pharmaceuticals Could Be on the Verge of a Breakout Year as AI, FDA Catalysts, and Mental Health Demand Converge
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us